Details of the Drug Reposition

General Information of This Drug (ID: DMVP5YE)

• Drug Name: Doxorubicin (DMVP5YE)
• Synonyms: doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

28 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Wilms tumor	DISB6T16	N.A.	Approved	[1]
Testicular lymphoma	DISC2M2N	N.A.	Approved	[1]
Splenic marginal zone lymphoma	DISCGTZY	N.A.	Approved	[1]
Primary systemic amyloidosis	DISIALGI	N.A.	Approved	[1]
Posterior urethra cancer	DIS3DNQW	N.A.	Approved	[1]
Ovarian neoplasm	DISEAFTY	N.A.	Approved	[1]
Ovarian disorder	DISHZX9D	N.A.	Approved	[1]
MALT lymphoma	DIS1AVVE	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[1]
Kidney neoplasm	DISBNZTN	N.A.	Approved	[1]
Hormone-resistant prostate carcinoma	DISM0MTO	N.A.	Approved	[1]
Hamartoma	DIS0I87H	N.A.	Approved	[1]
Fallopian tube neoplasm	DISHMMF2	N.A.	Approved	[1]
Childhood kidney Wilms tumor	DIS0NMK3	N.A.	Approved	[1]
Burkitt lymphoma	DIS9D5XU	N.A.	Approved	[1]
Breast carcinoma	DIS2UE88	N.A.	Approved	[1]
Beckwith-Wiedemann syndrome	DISH15GR	N.A.	Approved	[1]
Anterior urethra cancer	DISAKHZJ	N.A.	Approved	[1]
Adult kidney Wilms tumor	DIS79FJF	N.A.	Approved	[1]
Carcinoma	DISH9F1N	2A00-2F9Z	Approved	[1]
Acute myelogenous leukaemia	DISCSPTN	2A41	Approved	[1]
Plasma cell myeloma	DIS0DFZ0	2A83.1	Approved	[1]
Nodal marginal zone lymphoma	DIS7MP4T	2A85.0	Approved	[1]
Kaposi sarcoma	DISC1H1Z	2B57	Approved	[1]
Epithelial ovarian cancer	DIS56MH2	2B5D	Approved	[1]
Small-cell lung cancer	DISK3LZD	2C25.Y	Approved	[1]
Inflammatory breast cancer	DIS3QRWA	2C62	Approved	[1]
Thyroid cancer	DIS3VLDH	2D10	Approved	[1]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hepatocellular carcinoma	DIS0J828	2C12.02	Phase 3	[2]

2 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Papillary serous cystadenocarcinoma	DISZV6Z3	N.A.	Withdrawn	[3]
Ovarian cancer	DISZJHAP	2C73	Withdrawn	[4]

4 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ureter cancer	DISOUKYP	N.A.	Discontinued in Phase 3	[5]
Bone osteosarcoma	DIST1004	N.A.	Discontinued in Phase 3	[6]
Diffuse large B-cell lymphoma	DISSACK3	2A81	Discontinued in Phase 3	[7]
AIDS-related lymphoma	DISSLRAU	2B33.5	Discontinued in Phase 3	[8]

3 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Primary peritoneal serous adenocarcinoma	DISNCHKN	N.A.	Discontinued in Phase 2	[9]
Ovarian serous adenocarcinoma	DISSU72Z	N.A.	Discontinued in Phase 2	[10]
Ewing sarcoma	DISQYLV3	2B52	Discontinued in Phase 2	[11]

3 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Classic Hodgkin lymphoma	DISV1LU6	N.A.	Investigative	[1]
Follicular lymphoma	DISVEUR6	2A80	Investigative	[1]
Neuroblastoma	DISVZBI4	2D11.2	Investigative	[1]

References

• [1] Doxorubicin FDA Label
• [2] ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
• [3] Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
• [4] Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy nave Metastatic Melanoma
• [5] An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
• [6] Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
• [7] Dynepo Infrequent Dosing Study
• [8] A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
• [9] A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
• [10] Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
• [11] Methylprednisolone N Acetylcysteine in Hepatic Resections